Natasha Hernday
Directeur/Bestuurslid bij XOMA CORPORATION
Vermogen: 76 968 $ op 30-04-2024
Actieve functies van Natasha Hernday
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
SEAGEN INC. | Corporate Officer/Principal | 01-01-2011 | - |
XOMA CORPORATION | Directeur/Bestuurslid | 30-06-2020 | - |
Independent Dir/Board Member | 30-06-2020 | - |
Loopbaan van Natasha Hernday
Eerdere bekende functies van Natasha Hernday
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
ALPINE IMMUNE SCIENCES, INC. | Directeur/Bestuurslid | 10-12-2020 | 20-05-2024 |
Independent Dir/Board Member | 10-12-2020 | 20-05-2024 | |
PDL BIOPHARMA, INC. | Directeur/Bestuurslid | 24-06-2019 | 01-12-2022 |
Independent Dir/Board Member | 24-06-2019 | 01-12-2022 | |
AMGEN INC. | Corporate Officer/Principal | 01-07-1994 | 01-01-2010 |
Opleiding van Natasha Hernday
Pepperdine University | Masters Business Admin |
University of California, Santa Barbara | Undergraduate Degree |
Statistieken
Internationaal
Verenigde Staten | 8 |
Operationeel
Director/Board Member | 3 |
Independent Dir/Board Member | 3 |
Corporate Officer/Principal | 2 |
Sectoraal
Health Technology | 6 |
Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 3 |
---|---|
AMGEN INC. | Health Technology |
XOMA CORPORATION | Health Technology |
ALPINE IMMUNE SCIENCES, INC. | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Seagen Inc.
Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
PDL BioPharma, Inc.
PDL BioPharma, Inc. BiotechnologyHealth Technology PDL BioPharma, Inc. engages in the business of developing innovative therapeutics and healthcare technologies. It operates under the Medical Devices and Income Generating Assets segments. The Medical Devices segment focuses on the sale and lease of the LENSAR laser system which includes equipment, patient interface devices, procedure licenses, training, installation, warranty, and maintenance agreements. The Income Generating Assets segment offers notes and other long-term receivables; royalty rights, hybrid notes, and royalty receivables; equity investments; and royalties from issued patents covering the humanization of antibodies. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Reno, NV. | Health Technology |
- Beurs
- Insiders
- Natasha Hernday
- Ervaring